NCT05074589View on ClinicalTrials.gov

Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer

PHASE3CompletedINTERVENTIONAL

Enrollment

298

Participants

Timeline

Start Date

January 25, 2018

Primary Completion Date

November 18, 2021

Study Completion Date

March 10, 2022

Conditions

Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy

Interventions

DRUG

Irinotecan liposome、5-Fluorouracil、Leucovorin

DRUG

Placebo、5-Fluorouracil、Leucovorin

Trial Locations (1)

Unknown

Qinhuai Medical Area, General Hospital of PLA Eastern Theater Command, Nanjing

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT05074589 - Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer | Biotech Hunter | Biotech Hunter